TCRT — Alaunos Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.66
-$0.04 (-2.35%)
Alaunos Therapeutics Inc (TCRT) is a biotechnology company listed on NASDAQ. It is led by Holger Weis CPA, based in 501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301, with about 1 employees. Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Latest reported TCRT revenue for 2025-09-30 was $0. Net income was -$1.2M. TCRT currently screens at market cap $5.6M.
Use this TCRT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TCRT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TCRT SEC filings page. Lician reads the product cache first so this HTML stays unique to Alaunos Therapeutics Inc even when a live quote feed is slow.
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
TCRT Key Statistics
Market Cap
$5.63M
Volume
3,680
Previous Close
$1.79
Day Range
$1.69 – $1.79
P/B Ratio
4.42
EPS
-$2.92
Revenue
$10.00K
Net Income
-$4.68M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+100.0%
Profit Margin
-46790.0%
Employees
1
TCRT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.00K | $5.00K | $2.92M | $398.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$4.68M | -$35.14M | -$37.73M | -$78.75M |
| EPS (Diluted) | -$2.92 | -$21.97 | -$2.61 | -$0.37 |
Total Assets
$2.75M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.09M
Operating Cash Flow
-$4.97M
Free Cash Flow
$0.00
Alaunos Therapeutics Inc Company Information
- Chairman of the Board & CEO
- Holger Weis CPA
- Headquarters
- 501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
- Website
- www.alaunos.com
- Phone
- 346 355 4099
- IPO / Founded
- 2005-08-24
- Sector
- Healthcare
- Industry
- Biotechnology